 KRAS amplification is mutually exclusive with KRAS mutations.Tumors or cell lines harboring this genetic lesion are not responsive to EGFR inhibitors.Although KRAS amplification is an infrequent event in colorectal cancer, it might be responsible for precluding response to anti-EGFR treatment in some patients.